Structural epitope matching for HLA-alloimmunized thrombocytopenic patients: A new strategy to provide more effective platelet transfusion support?

Transfusion

Volumn 48, Issue 2, 2008, Pages 221-227

  Duquesnoy, Rene J ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HLA A ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN;

ALLOIMMUNIZATION; ARTICLE; BLOOD ANALYSIS; COMPUTER PROGRAM; HISTOCOMPATIBILITY; HLA MATCHING; HLA SYSTEM; HUMAN; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA;

AUTOIMMUNITY; BLOOD TRANSFUSION, AUTOLOGOUS; CROSS REACTIONS; EPITOPES; HLA ANTIGENS; HUMANS; PLATELET TRANSFUSION; PURPURA, THROMBOCYTOPENIC;

EID: 38349163614     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2007.01516.x     Document Type: Article

References (39)

1. Yankee RA, Grumet FC, Rogentine GN. Platelet transfusion therapy. The selection of compatible platelet donors for refractory patients by lymphocyte HLA typing. N Engl J Med 1969 281 : 1208 11.
2. Duquesnoy RJ, Filip DJ, Rodey GE, Rimm AA, Aster RH. Successful transfusion of platelets "mismatched" for HLA antigens to alloimmunized thrombocytopenic patients. Am J Hematol 1977 2 : 219 26.
3. Engelfriet CP, Reesink HW, Aster RH, Brand A, Tomson B, Claas FH, Contreras M, Navarrete C, Jorgensen J, Murphy MF, Curtis R, Waters AH, Panzer S, Kurz M. Management of alloimmunized, refractory patients in need of platelet transfusions. Vox Sang 1997 73 : 191 8.
4. Kickler TS, Ness PM, Braine HG. Platelet crossmatching. A direct approach to the selection of platelet transfusions for the alloimmunized thrombocytopenic patient. Am J Clin Pathol 1988 90 : 69 72.
5. Freedman J, Gafni A, Garvey MB, Blanchette V. A cost-effectiveness evaluation of platelet crossmatching and HLA matching in the management of alloimmunized thrombocytopenic patients. Transfusion 1989 29 : 201 7.
6. O'Connell B, Schiffer CA. Donor selection for alloimmunized patients by platelet crossmatching of random-donor platelet concentrates. Transfusion 1990 30 : 314 7.
7. Rebulla P, Morelati F, Revelli N, Villa MA. Outcomes of an automated procedure for the selection of effective platelets for patients refractory to random donors based on cross-matching locally available platelet products. Br J Haematol 2004 124 : 83 9.
8. Petz LD, Garratty G, Calhoun L, Clark BD, Terasaki PI, Gresens C, Gornbein JA, Landaw EM, Smith R, Cecka JM. Selecting donors of platelets for refractory patients on the basis of HLA antibody specificity. Transfusion 2000 40 : 1446 56.
9. Rodey GE, Fuller TC. Public epitopes and the antigenic structure of the HLA molecules. Crit Rev Immunol 1987 7 : 229 67.
10. Duquesnoy RJ, White LT, Fierst JW, Vanek M, Banner BF, Iwaki Y, Starzl TE. Multiscreen serum analysis of highly sensitized renal dialysis patients for antibodies toward public and private class I HLA determinants. Implications for computer-predicted acceptable and unacceptable donor mismatches in kidney transplantation. Transplantation 1990 50 : 427 37.
11. Rodey GE, Neylan JF, Whelchel JD, Revels KW, Bray RA. Epitope specificity of HLA class I alloantibodies. I. Frequency analysis of antibodies to private versus public specificities in potential transplant recipients. Hum Immunol 1994 39 : 272 80.
12. Zimmermann R, Wittmann G, Zingsem J, Zeiler T, Eckstein R. Identification of antibodies toward private and public class I HLA epitopes in sensitized patients. Infusionsther Transfusionsmed 1994 21 : 327 32.
13. Laundy GJ, Bradley BA, Rees BM, Younie M, Hows JM. Incidence and specificity of HLA antibodies in multitransfused patients with acquired aplastic anemia. Transfusion 2004 44 : 814 25.
14. Takemoto S, Gjertson DW, Terasaki PI. HLA matching: a comparison of conventional and molecular approaches. Clin Transpl 1992 413 34.
15. Duquesnoy RJ. HLAMatchmaker: a molecularly based algorithm for histocompatibility determination. I. Description of the algorithm. Hum Immunol 2002 63 : 339 52.
16. Duquesnoy RJ, Marrari M. HLAMatchmaker: a molecularly based algorithm for histocompatibility determination. II. Verification of the algorithm and determination of the relative immunogenicity of amino acid triplet-defined epitopes. Hum Immunol 2002 63 : 353 63.
17. Duquesnoy RJ, Takemoto S, De Lange P, Doxiadis II, Schreuder GM, Claas FH. HLAMatchmaker: a molecularly based algorithm for histocompatibility determination. III. Effect of matching at the HLA-A,B amino acid triplet level on kidney transplant survival. Transplantation 2003 75 : 884 9.
18. Duquesnoy RJ, Howe J, Takemoto S. HLAmatchmaker: a molecularly based algorithm for histocompatibility determination. IV. An alternative strategy to increase the number of compatible donors for highly sensitized patients. Transplantation 2003 75 : 889 97.
19. Nambiar A, Duquesnoy RJ, Adams S, Oblitas J, Leitman S, Stroncek D, Marincola F. HLAMatchmaker-driven analysis of response to HLA matched platelet transfusions in alloimmunized patients. Blood 2006 107 : 1680 7.
20. Rooney G, Dunne C, Laspinas S, Lawlor E, Woolfson M, Cummins F., Gough D. Provision of HLA matched platelets using HLAMatchmaker [abstract]. Tissue Antigens 2006 67 : 560.
21. Iniotaki-Theodoraki A, Kalogeropoulou E, Apostolaki M, Doxiadis I, Stavropoulos-Giokas C. Humoral sensitization against rejected grafts: specific antibodies to graft immunogenic amino acid triplets. Transplant Proc 2004 36 : 1728 31.
22. Goodman R, Taylor C, O'Rourke C, Lynch A, Bradley A, Key K. Utility of HLAMatchmaker and single-antigen HLA-antibody detection beads for identification of acceptable mismatches in highly sensitised patients awaiting kidney transplantation. Transplantation 2006 81 : 1331 6.
23. Claas FH, Witvliet M, Duquesnoy RJ, Persijn G, Doxiadis II. The acceptable mismatch program as a fast tool to transplant highly sensitized patients awaiting a post-mortal kidney: short waiting time and excellent graft outcome. Transplantation 2004 78 : 190 3.
24. Claas FH, Dankers MK, Oudshoorn M, van Rood JJ, Mulder A, Roelen DL, Duquesnoy RJ, Doxiadis II. Differential immunogenicity of HLA mismatches in clinical transplantation. Transplant Immunol 2005 14 : 187 91.
25. Doxiadis II, Duquesnoy RJ, Claas FH. Extending options for highly sensitized patients to receive a suitable kidney graft. Curr Opin Immunol 2005 17 : 536 40.
26. Duquesnoy RJ, Witvliet MJ, Doxiadis II, de Fijter H, Claas FH. HLAMatchmaker-based strategy to identify acceptable HLA class I mismatches for highly sensitized kidney transplant candidates. Transpl Int 2004 7 : 31 8.
27. Duquesnoy R. A structurally based approach to determine HLA compatibility at the humoral immune level. Hum Immunol 2006 67 : 847 62.
28. Duquesnoy RJ, Askar M. HLAMatchmaker: a molecularly based algorithm for histocompatibility determination V. Eplet matching for HLA-DR, HLA-DQ and HLA-DP. Hum Immunol 2007 68 : 12 25.
29. Brecher ME. Technical manual. 15th ed. Bethesda : American Association of Blood Banks 2005. p. 3 62 6.
30. Fuller AA, Trevithick JE, Rodey GE, Parham P, Fuller TC. Topographic map of the HLA-A2 CREG epitopes using human alloantibody probes. Hum Immunol 1990 28 : 284 305.
31. McElligott MC, Menitove JE, Duquesnoy RJ, Hunter JB, Aster RH. Effect of HLA Bw4/Bw6 compatibility on platelet transfusion responses of refractory thrombocytopenic patients. Blood 1982 59 : 971 5.
32. Duquesnoy R, Filip D, Tomasulo P, Aster R. Role of HLA-C matching in histocompatibilty platelet transfusion therapy of alloimmunized thrombocytopenic patients. Transplant Proc 1977 9 : 1827 9.
33. Mueller-Eckhardt G, Hauck M, Kayser W, Eckhardt C. HLA-C antigens on platelets. Tissue Antigens 1980 16 : 91 4.
34. Saito S, Ota S, Seshimo H, Yamazaki Y, Nomura S, Ito T, Miki J, Ota M, Fukushima H, Maeda H. Platelet transfusion refractoriness caused by a mismatch in HLA-C antigens. Transfusion 2002 42 : 302 8.
35. Adeyi O, Girnita A, Awadalla Y, Askar M, Shapiro R, Howe J, Martell J, Zeevi A, Nalesnik M, Rhandawa P, Demetris AJ, Serum analysis after kidney transplant nephrectomy reveals restricted antibody specificity patterns against donor HLA class I antigens. Transpl Immunol 2005 14 : 53 62.
36. Duquesnoy RJ, Claas FHJ. Progress Report of 14th International Histocompatibility Workshop Project on the Structural Basis of HLA Compatibility. Tissue Antigens 2007 69 Suppl 1 : 180 4.
37. Kao KJ, Mickel M, Braine HG, Davis K, Enright H, Gernsheimer T, Gillespie MJ, Kickler TS, Lee EJ, McCullough JJ, McFarland JG, Nemo GJ, Noyes WD The TRAP Study Group. White cell reduction in platelet concentrates and packed red cells by filtration: a multicenter clinical trial. Transfusion 1995 35 : 13 9.
38. Schiffer CA, Anderson KC, Bennett CL, Bernstein S, Elting LS, Goldsmith M, Goldstein M, Hume H, McCullough JJ, McIntyre RE, Powell BL, Rainey JM, Rowley SD, Rebulla PT, Troner MB, Wagnon AH. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001 19 : 1519 38.
39. Dankers MK, Witvliet MD, Roelen DL, De Lange P, Korfage N, Persijn GG, Duquesnoy RJ, Doxiadis II, Claas FH. The number of amino acid triplet differences between patient and donor is predicitve for the antibody reactivity against mismatched HLA antigens. Transplantation 2004 77 : 1236 9.